2022 Revenues ($USD) : $236,222,000
2022 R&D spend : $36,720,000
2022 Number of Employees : 750
Fiscal Year End : 6/30/2022
Company CEO : Scott Ward, CEO

St. Paul, Minnesota–based Cardiovascular Systems specializes in developing devices for peripheral and coronary artery disease. Its product lineup includes patented orbital atherectomy systems (OAS) for peripheral and coronary applications. In March 2022, the company named Dr. Jeffery Chambers as its chief medical officer. Chambers had previously served as the primary investigator for a pivotal trial for an investigational orbital atherectomy device used in coronary arteries. In the same month, the company announced results from first-in-human procedures using its Propel percutaneous ventricular assist device. The company noted that the Propel device performed as intended and provided uninterrupted hemodynamic support leading to successful revascularization. –BB